uniQure used 'distorted comparison' in Huntington's asset trial: FDA official
Source: SeekingAlpha
2026-03-05 19:27:49 ET
More on uniQure
- uniQure: Worst Case Scenario Becomes Reality
- uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade)
- uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
- uniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130
- UniQure outlines next steps for Huntington’s program as FDA recommends Phase III sham-controlled trial
Read the full article on Seeking Alpha
For further details see:
uniQure used 'distorted comparison' in Huntington's asset trial: FDA official
uniQure N.V.
NASDAQ: QURE
QURE Trading
33.38% G/L:
$17.42 Last:
10,231,137 Volume:
$18.015 Open:
QURE Latest News
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
